Global Heavy Metal Poisoning Treatment Market - 2023-2030

Global Heavy Metal Poisoning Treatment Market - 2023-2030

Global heavy metal poisoning treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Heavy metal poisoning is a medical condition that occurs when toxic heavy metals accumulate in the body. These metals, such as lead, mercury, cadmium, and arsenic, can enter the body through contaminated food, water, or exposure to certain occupations. The symptoms experienced and the severity of the poisoning depends on the type of metal involved and the level of exposure. Some common symptoms include neurological and cognitive problems, digestive issues, organ damage, and in severe cases, death.

The treatment for heavy metal poisoning varies depending on the specific metal involved and the severity of the poisoning. One common approach is chelation therapy, which involves administering chelating agents such as dimercaprol, DMSA, or EDTA.

Market Dynamics: Drivers and Restraints

The development of novel oral treatments for heavy metal poisoning is expected to drive the market growth

In 2022, the biotech startup HOPO Therapeutics, based in Berkeley, was co-founded by Hannah Weber, an MBA/MPH student at Berkeley Haas, along with scientists Julian Rees and Rebecca Abergel from Lawrence Berkeley National Laboratory. Their mission is to develop effective treatments for heavy metal poisoning. Their first product, called HOPO-101, is an innovative oral treatment designed to selectively bind to toxic metals, facilitating their safe removal from the body without affecting essential minerals.

Lead poisoning affects over 800 million children worldwide. HOPO Therapeutics is addressing this global health issue by planning to begin Phase 1 clinical trials soon. They aim to secure venture funding to support their mission of providing accessible, life-saving treatments for heavy metal poisoning. The company is seeking partnerships with physicians, governments, impact investors, and global health organizations to maximize their impact and distribution.

Furthermore, the high prevalence of heavy metal exposure, ongoing research and development, and governments and international organizations launching public health initiatives to combat heavy metal poisoning are the factors expected to drive the market over the forecast period.

Restraint:

Lack of awareness among the general population, high treatment costs and environmental challenges are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global heavy metal poisoning treatment market is segmented based on the type of heavy metal poisoning, treatment, route of administration, distribution channel and region.

The chelating agents from the treatment segment accounted for approximately 43.4% of the heavy metal poisoning treatment market share

Chelating agents are essential in the treatment of heavy metal poisoning, as they facilitate the removal of toxic metals from the body. These agents work by binding to heavy metals in the bloodstream, forming stable complexes that can be excreted through urine. This process helps reduce the concentration of harmful metals and mitigates their adverse effects on organs and tissues.

Chelating agents have several advantages, including their ability to selectively target toxic metals, sparing essential minerals, and reducing the risk of side effects. The market for chelating agents in heavy metal poisoning treatment is driven by factors such as the increasing awareness of heavy metal health risks, and a growing patient population suffering from heavy metal exposure.

For instance, National Lead Poisoning Prevention Week (NLPPW) is an annual event that aims to increase awareness of lead poisoning. The event brings together individuals, organizations, industry, and state, tribal, and local governments to reduce childhood exposure to lead. NLPPW is usually held in October, which is also Children's Health Month - a time to raise awareness about children's environmental health, including the dangers and potential health impacts of lead.

Geographical Analysis

North America accounted for approximately 42.1% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing acquisition, rising investment in the chelating agents, and growing product launches by the companies.

For instance, on August 10, 2022, Captura Biopharma a biotech company is developing and commercializing oral chelators to treat internal transuranic radionuclide contamination and heavy metal poisoning.

Exposure to these contaminants has been linked to severe health issues, including heart disease and cancer. Although the U.S. Environmental Protection Agency (EPA) has established maximum contaminant levels for these metals, they acknowledge that there is no safe level of exposure to either. Therefore, this research highlights the urgent necessity for accessible and targeted treatments to mitigate the health impacts of heavy metal exposure and emphasizes the importance of public health initiatives to address these disparities effectively.

COVID-19 Impact Analysis

The COVID-19 pandemic had several notable impacts on the heavy metal poisoning treatment market. Exposure to heavy metals can increase the risk of COVID-19 and other respiratory infections. Both smoking and PM2.5 pollution are associated with toxic metals that can cause respiratory dysfunction, immunotoxicity, and worsen viral diseases. People with HIV and those at high risk have higher levels of heavy metals in their bodies. A study on COVID-19 patients found that deceased cases had higher levels of cadmium in their blood.

Moreover, lockdowns, restrictions, and patient concerns about visiting healthcare facilities also led to delays in screenings and diagnoses. As heavy metal poisoning symptoms can be vague, these delays hindered early detection and intervention. In addition, the pandemic also affected research and development efforts related to new and improved heavy metal poisoning treatments. Clinical trials and drug development projects faced delays and setbacks, slowing the introduction of innovative treatment options. Despite the challenges, it is important to address heavy metal poisoning. The market is expected to recover as healthcare systems stabilize and R&D efforts regain momentum.

Market Segmentation:

By Type of Heavy Metal Poisoning
• Lead
• Mercury
• Arsenic
• Cadmium
• Thallium
• Aluminum
• Barium
• Others

By Treatment
• Chelating Agents
D-Penicillamine
• Medications
Dimercaprol
Dimercaptosuccinic acid (succimer)
Ethylenediaminetetraacetic acid (EDTA)
Penicillamine
• Others

By Route of Administration
• Parenteral Route
• Oral Route
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the heavy metal poisoning treatment market include SGPharma Pvt. Ltd., HOPO Therapeutics, Inc., Yashica Pharmaceuticals Private Limited., EmeraMed Limited, Captura Biopharma, Bausch Health Companies Inc., Midas Pharma GmbH, Recordati Rare Diseases Inc, and Lupin Pharmaceuticals, Inc. among others.

Key Development
• On August 10, 2022, Captura Biopharma and OceanTech Acquisitions I Corp. entered into a definitive business combination agreement that will result in Captura Biopharma becoming a publicly listed company on The Nasdaq Stock Market LLC. Captura Biopharma is an emerging biotechnology company that develops and commercializes oral chelators to treat internal transuranic radionuclide contamination and heavy metal poisoning. Upon completion of the transaction, OceanTech will be renamed Captura Biopharma Holdings, Inc. (the ""Combined Company"").
• On August 10, 2023, Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings Inc., launched Edetate calcium disodium injection in the United States. The launch is aimed at addressing a critical shortage of this important therapy.

Why Purchase the Report?
• To visualize the global heavy metal poisoning treatment market segmentation based on type of heavy metal poisoning, treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of heavy metal poisoning treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global heavy metal poisoning treatment market report would provide approximately 66 tables, 71 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies